Literature DB >> 18095745

Data resources for investigating drug exposure during pregnancy and associated outcomes: the General Practice Research Database (GPRD) as an alternative to pregnancy registries.

Rachel A Charlton1, Marianne C Cunnington, Corinne S de Vries, John G Weil.   

Abstract

Pregnancy registries are the most commonly used data resource for the post-marketing surveillance of drug teratogenicity. However, the limited sample size and potential selection bias in these registries has led us to investigate the potential of the UK General Practice Research Database (GPRD) as an alternative data source for monitoring drug safety during pregnancy. In addition, a literature review identified further observational data sources that monitor pregnancy outcomes for future evaluation. Initial feasibility studies focused on the ability of the GPRD to capture pregnancy outcomes for a range of drug class exposures, all of which are currently under investigation in pregnancy registries, during pregnancy. The comparator pregnancy registries were identified via a MEDLINE search, whilst eligible pregnancies, in which women received one or more prescriptions for the drug of interest during pregnancy, were identified in the GPRD using the mother-baby link. The number of pregnancy outcomes following exposure to medication for a range of conditions with varying prevalence, including depression, migraine, epilepsy, herpes simplex and HIV, captured by the two data sources were compared. For depression, a relatively prevalent condition, the GPRD recorded the same number of mean annual intrauterine exposures to fluoxetine as the pregnancy registry (118 exposures/year). Ascertainment of intrauterine exposure to drug treatments for less prevalent conditions was found to be higher for the pregnancy registries than the GPRD; for the older antiepileptic drugs (valproate and carbamazepine), the pregnancy registry recorded between four and five times as many mean annual exposures as the GPRD. Virtually no antiretroviral exposures (three) were identified during the time period of interest on the GPRD, compared with 3946 in the Antiretroviral Pregnancy Registry. Data from the GPRD meet established criteria for evaluating outcomes of pregnancy. For prevalent conditions, it has the potential to replace or work alongside standard pregnancy registries and the alternative data sources identified. Further studies are now needed to assess its ability to replicate known teratogenic associations.

Entities:  

Mesh:

Year:  2008        PMID: 18095745     DOI: 10.2165/00002018-200831010-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  25 in total

1.  Do pregnant women report use of dispensed medications?

Authors:  C Olesen; C Søndergaard; N Thrane; G L Nielsen; L de Jong-van den Berg; J Olsen
Journal:  Epidemiology       Date:  2001-09       Impact factor: 4.822

2.  How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper.

Authors:  Jørn Olsen; Andrew Czeizel; Henrik Toft Sørensen; Gunnar Lauge Nielsen; Lolkje T W de Jong van den Berg; Lorentz M Irgens; Charlotte Olesen; Lars Pedersen; Helle Larsen; Rolv T Lie; Corinne S de Vries; Ulf Bergman
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Systematic identification of drugs that cause birth defects--a new opportunity.

Authors:  Allen A Mitchell
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

Review 4.  Mini-review: history of organized teratology information services in North America.

Authors:  M Leen-Mitchell; L Martinez; S Gallegos; J Robertson; J C Carey
Journal:  Teratology       Date:  2000-04

5.  Assessing teratogenicity of antiretroviral drugs: monitoring and analysis plan of the Antiretroviral Pregnancy Registry.

Authors:  Deborah L Covington; Hugh Tilson; Jenna Elder; Peggy Doi
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-08       Impact factor: 2.890

6.  Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.

Authors:  J Morrow; A Russell; E Guthrie; L Parsons; I Robertson; R Waddell; B Irwin; R C McGivern; P J Morrison; J Craig
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09-12       Impact factor: 10.154

Review 7.  EUROCAT: 25 years of European surveillance of congenital anomalies.

Authors:  H Dolk
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-09       Impact factor: 5.747

8.  ECLAMC: the Latin-American collaborative study of congenital malformations.

Authors:  Eduardo E Castilla; Iêda M Orioli
Journal:  Community Genet       Date:  2004

9.  Registration of congenital malformations in Denmark.

Authors:  K Christensen; L B Knudsen
Journal:  Dan Med Bull       Date:  1998-02

10.  Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study.

Authors:  De-Kun Li; Liyan Liu; Roxana Odouli
Journal:  BMJ       Date:  2003-08-16
View more
  17 in total

1.  Patterns of prescription of antidepressants and antipsychotics across and within pregnancies in a population-based UK cohort.

Authors:  Andrea V Margulis; Elizabeth M Kang; Tarek A Hammad
Journal:  Matern Child Health J       Date:  2014-09

2.  Drugs and Birth Defects: a knowledge database providing risk assessments based on national health registers.

Authors:  Ulrika Nörby; Karin Källén; Birgit Eiermann; Seher Korkmaz; Birger Winbladh; Lars L Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2012-09-26       Impact factor: 2.953

Review 3.  Prescribing without evidence - pregnancy.

Authors:  Simon H L Thomas; Laura M Yates
Journal:  Br J Clin Pharmacol       Date:  2012-10       Impact factor: 4.335

Review 4.  Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.

Authors:  Jennifer Weston; Rebecca Bromley; Cerian F Jackson; Naghme Adab; Jill Clayton-Smith; Janette Greenhalgh; Juliet Hounsome; Andrew J McKay; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2016-11-07

5.  Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD.

Authors:  Rachel A Charlton; John G Weil; Marianne C Cunnington; Corinne S de Vries
Journal:  Drug Saf       Date:  2010-09-01       Impact factor: 5.606

6.  Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations.

Authors:  Rachel A Charlton; John G Weil; Marianne C Cunnington; Sayantani Ray; Corinne S de Vries
Journal:  Drug Saf       Date:  2011-02-01       Impact factor: 5.606

7.  The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.

Authors:  Shanu Kohli Kurd; Andrea B Troxel; Paul Crits-Christoph; Joel M Gelfand
Journal:  Arch Dermatol       Date:  2010-08

8.  Medical databases in studies of drug teratogenicity: methodological issues.

Authors:  Vera Ehrenstein; Henrik T Sørensen; Leiv S Bakketeig; Lars Pedersen
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

9.  The safety of asthma medications during pregnancy and lactation: Clinical management and research priorities.

Authors:  Christina D Chambers; Jerry A Krishnan; Lorene Alba; Jessica D Albano; Allison S Bryant; Melanie Carver; Lee S Cohen; Elena Gorodetsky; Sonia Hernandez-Diaz; Margaret A Honein; Bridgette L Jones; Richard K Murray; Jennifer A Namazy; Leyla Sahin; Catherine Y Spong; Kaveeta P Vasisht; Kevin Watt; Keele E Wurst; Lynne Yao; Michael Schatz
Journal:  J Allergy Clin Immunol       Date:  2021-03-10       Impact factor: 14.290

10.  A Validation Study on the Frequency and Natural History of Miscarriages Using the Spanish Primary Care Database BIFAP.

Authors:  Sara Sanchez Ortiz; Consuelo Huerta; Ana Llorente-García; Paloma Ortega; Paloma Astasio; Lucía Cea-Soriano
Journal:  Healthcare (Basel)       Date:  2021-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.